Top Industry Leaders in the Adenomyosis Treatment Market
Latest Adenomyosis Treatment Companies Updates:
Myovant Sciences: Their GnRH antagonist, relugolix, is undergoing Phase 3 clinical trials as a potential non-surgical treatment for adenomyosis pain. Positive results could significantly expand treatment options.
Bayer: Their HIF-1 inhibitor, BAY1895344, demonstrated promising pain reduction in a Phase 2b study for adenomyosis. Further trials are planned to solidify its potential.
Excision Therapeutics: Their investigational gene therapy, EXT2-GTX, offers a novel approach to addressing the underlying cause of adenomyosis. Early-stage trials are ongoing, generating excitement for future possibilities
Olympus: Launched their next-generation ultrasonic tissue dissector, offering improved precision and minimal tissue damage in laparoscopic adenomyosis surgeries.
Intuitive Surgical: Introduced new features for their da Vinci robotic surgery system, aiming to enhance surgeon control and minimize complications in adenomyosis ablation procedures.
Myotronics: Developed a radiofrequency ablation device specifically designed for treating adenomyosis through minimally invasive uterine fibroid embolization (UFE) procedures.Genea: Their endometrial biopsy tool with integrated gene expression analysis allows for personalized risk assessment and treatment selection for adenomyosis patients.
List of Adenomyosis Treatment Key companies in the market:
- Mayne Pharma Group Limited
- Accord Healthcare
- Tolmar Pharmaceuticals, Inc.
- Boehringer Ingelheim International GmbH
- TerSera Therapeutics LLC
- Ferring B.V.
- Lannett
- Par Pharmaceutical
- Hikma Pharmaceuticals PLC
- Context Therapeutics Inc